GlassScriptPhysician profile
Gerald V Levy
NPI 1154306306
$5,248.49
in general payments reported to CMS, 2019-2025
26 companies · $265 in 2025
The $265 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,236 · 2020: $435 · 2021: $352 · 2022: $1,030 · 2023: $807 · 2024: $1,123 · 2025: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,194.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,188.44 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $1,157.21 | 2019-2025 | |
| Bard Peripheral Vascular, INC. | $347.29 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $320.74 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $316.34 | 2019-2025 | Watchman Flx |
| Pfizer INC. | $273.09 | 2022-2025 | |
| Abbott Laboratories | $225.46 | 2022-2024 | Jot Dx |
| Astrazeneca Pharmaceuticals LP | $192.60 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $171.66 | 2019-2024 | Praluent, Evkeeza |
| Shockwave Medical, INC | $167.46 | 2022 | |
| Abiomed | $144.14 | 2019 | |
| Acist Medical Systems, INC. | $109.82 | 2022-2023 | |
| Terumo Medical Corporation | $84.65 | 2020-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $83.54 | 2019-2024 | Lifevest |
| Merck Sharp & Dohme LLC | $81.98 | 2024 | Verquvo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $63.25 | 2024 | Ozempic |
| Lemaitre Vascular, INC. | $61.06 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $48.59 | 2022-2023 | Camzyos |
| Cleerly, INC. | $36.06 | 2024 | Cleerly Ischemia, Cleerly Labs |
| Kiniksa Pharmaceuticals, LTD. | $35.47 | 2022-2023 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $29.97 | 2022-2024 | |
| Bsn Medical INC | $29.55 | 2022 | |
| Osprey Medical INC | $29.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.76 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.26 | 2025 | Jardiance |
| Medtronic Vascular, INC. | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Levy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.